Dackiw Alan P B, Zeiger Martha
Division of Endocrine and Oncologic Surgery, Department of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD 21287 USA.
Surg Clin North Am. 2004 Jun;84(3):817-32. doi: 10.1016/j.suc.2004.03.001.
The authors believe that total or near total thyroidectomy followed by 131I ablation and thyroid hormone suppression therapy are there commended extent of surgery and treatment of choice in differentiated thyroid cancer. This is based on retrospective data showing that total thyroidectomy plus 131I and thyroid stimulating hormone (TSH) suppression reduces disease recurrence and mortality, removes all intrathyroidal cancer, and facilitates the use of 131I scans and thyroglobulin measurements to monitor for recurrence. Recent decision analyses supporting this recommendation are summarized in this article. The recommendation comes with the caveat that total thyroidectomy must be performed safely with a low complication rate. With the institution of this appropriate treatment regimen, the prognosis for the majority of our patients with differentiated thyroid cancer is excellent.
作者认为,全甲状腺切除术或近全甲状腺切除术,随后进行碘-131消融和甲状腺激素抑制治疗,是分化型甲状腺癌推荐的手术范围和治疗选择。这是基于回顾性数据表明,全甲状腺切除术加碘-131和促甲状腺激素(TSH)抑制可降低疾病复发率和死亡率,清除所有甲状腺内癌,并便于使用碘-131扫描和甲状腺球蛋白测量来监测复发情况。本文总结了近期支持该建议的决策分析。该建议有一个前提条件,即全甲状腺切除术必须安全进行且并发症发生率低。采用这种适当的治疗方案,大多数分化型甲状腺癌患者的预后良好。